Gritgen

Gritgen Therapeutics Co., Ltd. was founded in 2019. With the vision of "Contributing to the Rise of China and the Happiness and Health of its People," the company focuses on independent innovation and R&D, aiming to become a world-leading biotechnology company based in China that benefits human health. The company has developed a globally leading high-efficiency vector platform through its proprietary research, with liver gene delivery as the entry point. Its lead product targets the broad and unmet needs of Hemophilia A patients, and it is currently the first product in China to enter the exploratory clinical trial stage, having already achieved promising safety and efficacy data. In the future, building upon the scientific foundation of its founders and team, the company will expand into therapeutic products for neurological disorders, balancing its pipeline between rare diseases and common illnesses while steadily advancing into clinical trials. Currently, the company has initiated the construction of an 8,600-square-meter cGMP production base in Suzhou Industrial Park, which includes a full-chain experimental platform for new drug R&D and production, covering plasmid, viral vector, and other related functions such as R&D, manufacturing, and quality control. Additionally, the company operates a 1,600-square-meter R&D center in Changping Life Science Park, Beijing, equipped with complete biochemical laboratories and animal facilities, primarily used for early-stage independent drug discovery.